-- Over the past decade, lipid nanoparticles (LNPs) have quietly evolved from a niche formulation tool into one of the most transformative technologies in modern biomedicine. Today, they stand at the center of a new therapeutic frontier—powering advances in gene editing, long‑acting protein expression, cell engineering, and next‑generation vaccines. As researchers push toward more complex and durable genetic interventions, the demand for smarter, more adaptable LNP systems has never been greater.
Creative Biolabs, as a global leader in lipid‑based drug delivery technologies, offers advanced LNP formulation services and an expanded catalog of LNP products, designed to accelerate breakthroughs in gene therapy, vaccines, gene editing, and long‑term therapeutic protein delivery.
"Our team of liposome specialists has been deeply engaged in the development and refinement of LNP formulations, leveraging the cutting-edge LipoDrive™ technology to create a range of reliable LNP compositions and well-established manufacturing methods," said the director at Creative Biolabs.
A Fully Integrated LNP Development Engine
Creative Biolabs' upgraded LNP development service provides end‑to‑end support—from nucleic acid design and mRNA production to formulation, encapsulation, characterization, and scale‑up manufacturing. The platform leverages proprietary lipid formulations and advanced microfluidic technology to achieve high encapsulation efficiency, uniform particle size distribution, and reliable transfection performance across diverse immune cell populations, including macrophages, dendritic cells, NK cells, and T cells.
Expanded Portfolio of Ready‑to‑Use LNP Products
Creative Biolabs now offers an extensive catalog of ready‑to‑use LNP formulations featuring diverse ionizable lipids and nucleic acid payloads.
These include reporter gene LNPs, targeted LNPs for organs such as the liver, lung, spleen, and T cells, and empty LNP controls for formulation screening. All products exhibit uniform particle size (~100 nm), high stability, and encapsulation efficiencies exceeding 85%.
The portfolio supports applications in mRNA delivery, gene editing, CAR‑T cell engineering, and tissue‑specific targeting using SORT technology, enabling researchers to rapidly evaluate and deploy optimized LNP systems.
Breakthrough Capabilities for Prolonged Gene Expression
In a significant advancement for long‑term gene therapy, Creative Biolabs has introduced specialized services for DNA‑based LNPs designed to achieve durable gene expression. Unlike mRNA, plasmid DNA can persist as a stable episome within the nucleus, enabling sustained transcription and long‑lasting therapeutic protein production—ideal for chronic disease applications. To overcome the unique challenges of DNA delivery, the company leverages insights from recent multi‑step LNP screening research.
Learn more about LNP solutions or advanced DNA‑based delivery strategies, please visit https://www.creative-biolabs.com/lipid-based-delivery/.
About Creative Biolabs
Creative Biolabs is dedicated to advancing the future of genetic medicine through cutting‑edge lipid‑based delivery technologies. By combining innovative lipid design, high‑fidelity formulation, and deep biological insight, Creative Biolabs empowers scientists and developers worldwide to overcome delivery barriers and accelerate the translation of genetic ideas into real‑world solutions.
Contact Info:
Name: Candy Swift
Email: Send Email
Organization: Creative Biolabs
Address: 17 Ramsey Road, Shirley, NY 11967, USA
Phone: 6318306441
Website: https://www.creative-biolabs.com/lipid-based-delivery/
Release ID: 89188750
Google
RSS